| Andrew Vasyluk, MD | |
|
5415 Cardinal Square Blvd, Saginaw, MI 48604-8200 | |
| (989) 790-4855 | |
| Not Available |
| Full Name | Andrew Vasyluk |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 9 Years |
| Location | 5415 Cardinal Square Blvd, Saginaw, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215316518 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 4301107480 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Covenant Medical Center | Saginaw, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Covenant Medical Center Inc | 2769387778 | 380 |
News Archive
Noting "the 2013 Sahel Regional Strategy calls for $1.66 billion to help meet humanitarian needs and build up resilience among vulnerable groups - an identical figure to the 2012 crisis appeal - even though aid agencies estimate the number of Sahelians at risk of going hungry this year has dropped 44 percent to 10.3 million," IRIN examines "why the ask has remained constant."
Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.
Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of Otolaryngology-Head and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.
Stem cell have been the main focus of healing therapy research because they can morph into new cells, and using a patient's own stem cells will not induce an autoimmune response. For healing after a heart attack, the ideal time to administer these therapies is when reopening the clogged blood vessel because the heart is easily accessible. While stem cells show promise for heart attack treatment, the process of harvesting and reintroducing the cells—which can take days or weeks—is too slow for this window.
› Verified 6 days ago
| Entity Name | Covenant Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972590412 PECOS PAC ID: 2769387778 Enrollment ID: O20031209000107 |
News Archive
Noting "the 2013 Sahel Regional Strategy calls for $1.66 billion to help meet humanitarian needs and build up resilience among vulnerable groups - an identical figure to the 2012 crisis appeal - even though aid agencies estimate the number of Sahelians at risk of going hungry this year has dropped 44 percent to 10.3 million," IRIN examines "why the ask has remained constant."
Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.
Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of Otolaryngology-Head and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.
Stem cell have been the main focus of healing therapy research because they can morph into new cells, and using a patient's own stem cells will not induce an autoimmune response. For healing after a heart attack, the ideal time to administer these therapies is when reopening the clogged blood vessel because the heart is easily accessible. While stem cells show promise for heart attack treatment, the process of harvesting and reintroducing the cells—which can take days or weeks—is too slow for this window.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Vasyluk, MD 26136 Cunningham Dr, Warren, MI 48091-1109 Ph: (586) 863-6752 | Andrew Vasyluk, MD 5415 Cardinal Square Blvd, Saginaw, MI 48604-8200 Ph: (989) 790-4855 |
News Archive
Noting "the 2013 Sahel Regional Strategy calls for $1.66 billion to help meet humanitarian needs and build up resilience among vulnerable groups - an identical figure to the 2012 crisis appeal - even though aid agencies estimate the number of Sahelians at risk of going hungry this year has dropped 44 percent to 10.3 million," IRIN examines "why the ask has remained constant."
Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.
Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of Otolaryngology-Head and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.
Stem cell have been the main focus of healing therapy research because they can morph into new cells, and using a patient's own stem cells will not induce an autoimmune response. For healing after a heart attack, the ideal time to administer these therapies is when reopening the clogged blood vessel because the heart is easily accessible. While stem cells show promise for heart attack treatment, the process of harvesting and reintroducing the cells—which can take days or weeks—is too slow for this window.
› Verified 6 days ago
Felipe Andres Pacheco Granda, MD Surgery Medicare: Medicare Enrolled Practice Location: 1000 Houghton Ave, Saginaw, MI 48602 Phone: 989-746-7857 Fax: 989-746-7721 | |
Christina Lynn Maser, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 912 S Washington Ave Ste 1, Saginaw, MI 48601 Phone: 989-790-1001 | |
Dr. Ronald A Bays, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4701 Towne Centre Rd, Suite 202, Saginaw, MI 48604 Phone: 989-790-2600 Fax: 989-790-3311 | |
Dr. Faiz Tuma, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 912 S Washington Ave, Saginaw, MI 48601 Phone: 989-583-6800 Fax: 989-583-6955 | |
Sujal G Patel, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 5415 Cardinal Square Blvd, Saginaw, MI 48604 Phone: 989-583-5680 Fax: 989-790-7335 | |
Todd G Richardson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 5415 Cardinal Square Blvd, Saginaw, MI 48604 Phone: 989-583-5680 Fax: 989-790-7335 | |
Dr. Wael Solh, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 912 S Washington Ave Ste 1, Saginaw, MI 48601 Phone: 989-790-1001 Fax: 989-790-1002 |